Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 6,616

Document Document Title
WO/2011/146850A1
Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, seroton...  
WO/2011/145669A1
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...  
WO/2011/137089A1
Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of disease...  
WO/2011/136484A1
Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits high luminous efficiency in blue color and excellent life property, i...  
WO/2011/132712A1
Provided is a novel compound that is useful as a medical drug in that said compound displays strong antimicrobial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant strains thereof, on the basis of ...  
WO/2011/131316A1
A process for preparing 4-(4-aminophenyl)morpholin-3-one from 4-(4-nitrophenyl)morpholin-3-one by reducing the nitro group with hydrogen, characterized in that the reaction is effected in water or a mixture of a water-miscible solvent an...  
WO/2011/130194A2
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantiall...  
WO/2011/072257A3
There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.  
WO/2011/121068A1
The present invention concerns amino derivatives of cyclohex-2-enone of formula (I) and the salts thereof. Said derivatives have proved to be particularly effective as antioxidants in the treatment of cellular oxidative stress, especiall...  
WO/2011/121309A1
A compound having the formula (1) wherein W represents N or CH; R1 represents H or C1-3 alkyl; R2 represents a N-containing heterocyclyl ring or a -C1-3 alkylene-N-containing heterocyclyl group; in which any N-containing heterocyclyl com...  
WO/2011/120604A1
The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are...  
WO/2011/118672A1
Disclosed is a pharmaceutical product, particularly a pharmaceutical composition having a plasma kallikrein inhibition activity and is useful as a prophylactic or therapeutic agent for edemas (particularly hereditary vascular edema and c...  
WO/2011/117254A1
Compounds of formula (I) or pharmaceutically acceptable salts thereof, are useful for the treatment of diabetes and obesity.  
WO/2011/107903A1
The present invention provides for highly pure mosapride citrate dihydrate and processes for its preparation. The present invention further provides a process for the preparation of mosapride citrate dihydrate substantially free of impur...  
WO/2011/104127A1
The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH2 or CO; Y...  
WO/2011/105700A1
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Since the organic electroluminescent compounds exhibit high luminous efficiency in blue color, and excellent life proper...  
WO/2011/103435A2
Described are methods of forming protected boronic acids that provide in a manner that is straightforward, scalable, and cost-effective a wide variety of building blocks, such as building blocks containing complex and/or pharmaceutically...  
WO/2011/098501A1
The present invention relates to the use of a compound having the formula (II) for the preparation of a compound having the formula (V). Methods of preparing the compound having the formula (V) using the compound having the formula (II) ...  
WO/2011/093603A1
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property, it may be used...  
WO/2011/088877A1
The present invention relates to compounds according to formula (I), to the use thereof in organic electronic devices, and to organic electronic devices that contain compounds according to formula (I), preferably as hole transport materi...  
WO/2010/149578A3
Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 a...  
WO/2011/077726A1
Disclosed is a compound represented by formula (1) (wherein X, R1, R2a, R2b, R3a, R3b, R4a, R4b, ring A, Y, and the dashed line are described in the description), a pharmaceutically acceptable salt thereof, or a solvate of either, as an ...  
WO/2011/079105A1
The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are...  
WO/2011/076678A1
The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, ha...  
WO/2011/076930A1
The present invention concerns cyclic hidroxylamine derivatives of formula (I), and the salts thereof. Said derivatives have proved to be particularly effective as antioxidants for treating cellular oxidative stress, particularly in the ...  
WO/2011/073276A1
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein E, Z, m, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases...  
WO/2011/073273A1
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, p, E, X, R1, R2, R3, R4 R5 and R6 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of...  
WO/2011/072345A1
The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprisin...  
WO/2011/071136A1
A therapeutic agent for fibromyalgia, comprising a 5-HT2C receptor agonist as an active ingredient.  
WO/2011/071135A1
Disclosed is a compound or the like which serves as a prophylactic or therapeutic agent for diseases induced by the production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound represented by formul...  
WO/2011/072257A2
There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.  
WO/2011/071109A1
Disclosed is a compound or the like which serves as a prophylactic or therapeutic agent for diseases induced by the production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound represented by formul...  
WO/2011/069934A1
The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)- phenyl]-amide derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing the...  
WO/2011/070029A1
This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula (I) wherein R1 to R5 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are B...  
WO/2011/067306A1
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a p...  
WO/2011/064897A1
Disclosed is a bis-benzoxazinone compound which has high purity without substantially containing an alkali metal salt and forms a resin composition having excellent hydrolysis resistance when the compound is incorporated in a resin. The ...  
WO/2011/066394A1
The present invention is directed towards a new class of semi-conducting nonacene derivatives. These compounds are all soluble species and they all possess superior resistance to oxidation as compared to their counterparts that lack the ...  
WO/2011/057892A1
The present invention provides novel 2,3-dihydrobenzazine compounds of the formula (I), the pharmaceutically acceptable salts thereof, the N-oxides thereof and the pharmaceutically acceptable salts of said N-oxides. Formula (I) X is O or...  
WO/2011/032634A8
The invention relates to a method for producing compounds according to formula (I), wherein the hydrogen atom bound to the nitrogen is replaced with a metal atom from the series of alkali metals or alkaline-earth metals or with an alumin...  
WO/2011/000532A3
The invention relates to a method for producing compounds of the formula A1, wherein the carbon atom to which both the CF3 group and the hydroxy group are bonded is a stereocenter having either the R or the S configuration and wherein R1...  
WO/2011/047432A1
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...  
WO/2011/049241A1
Disclosed is an organic electroluminescent element which comprises: an anode; a cathode; a light-emitting layer that is arranged between the anode and the cathode and contains a first light-emitting layer material that contains a phospho...  
WO/2011/046954A1
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...  
WO/2011/038572A1
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, partic...  
WO/2011/035518A1
Pyrimidine derivatives and analogs, their pharmaceutically acceptable salts, processes for preparing them, pharmaceutical compositions comprising them, and their use in manufacture of medicaments for treating inflammatory and infectious ...  
WO/2010/102212A3
The present application is related to compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders associated with p75 expression, such as degradation or dysfunction of cells expressing p75 i...  
WO/2011/032634A1
The invention relates to a method for producing compounds according to formula (I), wherein the hydrogen atom bound to the nitrogen is replaced with a metal atom from the series of alkali metals or alkaline-earth metals or with an alumin...  
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2011/030955A1
An indenone derivative of formula (1) is effective in enhancing the activity of osteoblastic cells and inhibiting bone resorption by osteoclastic cells, and a pharmaceutical composition comprising the indenone derivative or a pharmaceuti...  
WO/2011/031620A1
The invention provides solid compositions comprising (S)-3-(4'-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichlor o-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)- 2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbon y...  

Matches 451 - 500 out of 6,616